Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
NCT Number: NCT03193879
Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a variety of respiratory diseases, including COPD and asthma. This study focus on the effects of PM on the pulmonary function and acute exacerbation of COPD and asthma patients in China, where PM exposure is much heavier than the United States and European countries.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Beijing, Beijing Municipality, 100730, China
Particulate matter(PM) exposure has been shown to increase the morbidity and mobility of a variety of respiratory diseases, including COPD and asthma. This study focus on the effects of PM on the pulmonary function and acute exacerbation of COPD and asthma patients in China, where PM exposure is much heavier than the United States and European countries. This study is an observational study which lasts 3 years. Primary outcome measures:Change in spirometry (FEV1) of COPD, asthma patients and healthy volunteers in response to different exposure doses of PM.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
Spirometry will be assessed at baseline and through study completion, an average of 2 years.
Time frame: 2 years
Patients will be followed up through study completion, an average of 2 years.
Peking Union Medical College Hospital
Other
Effects of Particulate Matter on the Lung Function and Acute Exacerbation of COPD and Asthma Patients--A Multi-center Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01728571
Asthma, Bronchial Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT03203603
Asthma, Bronchial Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT03206710
Asthma, Bronchial Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT05023876
COPD, Chronic Disease
Istanbul, Turkey (Türkiye)
View Trial Details